Last updated: February 24, 2026
What is the drug with NDC 76282-0575?
NDC 76282-0575 corresponds to Rupatadine, an antihistamine used to treat allergic rhinitis and urticaria. It is marketed primarily outside the U.S., with limited availability in the U.S. market. The drug is recognized for its efficacy in reducing allergy symptoms, with a favorable safety profile and a once-daily dosing regimen.
Current Market Landscape
Global Market Overview
The antihistamine market is segmented into first-generation (e.g., diphenhydramine, chlorpheniramine) and second-generation (e.g., loratadine, cetirizine, levocetirizine, rupatadine). Second-generation agents dominate because of their fewer sedative side effects.
In 2022, the global antihistamine market was valued at approximately $4.3 billion, with a compound annual growth rate (CAGR) of 4.2%. The Asia-Pacific region accounted for nearly 40% of sales, driven by high allergy prevalence and increasing healthcare access.
Rupatadine-Specific Data
- Market penetration is mainly in Europe, Latin America, and parts of Asia.
- Key competitors include cetirizine, loratadine, levocetirizine, desloratadine.
- Rupatadine faces limited competition in its unique dual H1-antihistamine and PAF receptor antagonism profile, which may offer differentiated therapeutic benefits.
Regulatory Status
- Approved in Europe (as Rupafin), Latin America, and some Asian countries.
- Not widely approved in the U.S., limiting its market reach domestically.
Pricing Benchmarks
- Average wholesale price (AWP): €4.50-€7.50 ($4.80-$8.00) per tablet depending on strength and country.
- In markets where it is marketed, retail prices range from $10-$20 per month in subscription models.
Price Projection Factors
Market Entry Potential in the U.S.
- No current FDA approval.
- A new formulation or indication could expand market access.
- Approval would position rupatadine as a second-generation antihistamine alternative, potentially capturing 5-10% of the existing antihistamine market over five years.
Pricing Strategy and Revenue Estimates
- Entry price point comparable to existing second-generation antihistamines.
- In markets with established use, prices are approximately $10-$20 per month retail.
- Based on annual sales forecasts (assuming moderate adoption), projected revenues could reach $50-$150 million annually within 3-5 years post-approval in regulated markets.
Competitive Dynamics
- Dominated by cetirizine ($9-$15/month), loratadine ($8-$14/month).
- Rupatadine offers potential differentiation via dual PAF antagonism, which may justify premium pricing if marketed with evidence of superior efficacy or reduced side effects.
Cost and Pricing Considerations
- Manufacturing costs are estimated at $1-$2 per tablet.
- Pricing must consider reimbursement frameworks, especially in North America and Europe.
- Patent landscape suggests key patents expire between 2023-2025, opening opportunities for generic competition that could lower prices.
Price Decline Trends
- Generic entry typically reduces prices by 50-70% over 2-3 years.
- Patented products tend to sustain higher prices initially, but market saturation leads to price reductions.
Forecast Summary
| Scenario |
Year 1 |
Year 3 |
Year 5 |
| High Adoption |
$150M |
$200M |
$250M |
| Moderate Adoption |
$50M |
$120M |
$180M |
| Low Adoption |
$25M |
$50M |
$75M |
Growth assumptions hinge on regulatory approval, market penetration, and competitive responses.
Conclusion
While the U.S. market for rupatadine remains inactive, substantial opportunity exists, particularly in regions where it is already approved. Price points mirror established second-generation antihistamines, with later adjustments following patent expiry and generic competition.
Key Takeaways
- Rupatadine has a niche market outside the U.S., with growth driven by allergy prevalence and differentiated mechanism.
- Market entry in the U.S. hinges on FDA approval, with pricing likely aligned to existing antihistamines initially.
- Revenue projections forecast up to $250 million annually within five years if approval and market penetration are successful.
- Price decline trends post-patent expiration could significantly reduce pricing, affecting long-term revenue.
- Competition will pressure pricing, especially after patent expiry, requiring strategic positioning.
FAQs
1. What are the primary barriers to market entry for rupatadine in the U.S.?
FDA approval processes, patent considerations, and establishing a distribution network.
2. How does rupatadine differentiate itself from other second-generation antihistamines?
Through its dual H1 and PAF antagonism, potentially offering improved efficacy in allergic responses.
3. What are the patent expiry dates that could impact future pricing?
Key patents are expected to expire between 2023 and 2025, allowing generic competition.
4. How does regional pricing vary for rupatadine?
European prices average €4.50-€7.50 per tablet; in Latin America and Asia, prices tend to be lower, often retailing for $10-$20 per month.
5. What strategies could companies adopt to maximize market share?
Accelerate FDA approval, emphasize the dual mechanism's benefits, and competitively price post-patent expiry with generics in mind.
References
[1] MarketWatch. (2022). Global antihistamine market report.
[2] IQVIA. (2022). Regional antihistamine sales data.
[3] European Medicines Agency. (2022). Rupatadine approval status.
[4] US Food and Drug Administration. (2023). Drug approval pipeline.
[5] IMS Health. (2022). Prescription price trends.
